Home › Upcoming votes › NRX Pharmaceuticals, Inc.
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in NRX Pharmaceuticals, Inc.’s proxy statement, with the board’s recommendation on each item. The company has filed 1 set of additional materials since; they can add to or change what is below, so check them before relying on it.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | ELECTION OF CLASS II DIRECTORS Director election |
Board | For | 2 nominees; support 92% to 92% |
| 2 | RATIFICATION OF SELECTION OF AUDITORS Auditor |
Board | For | 99% support |
From NRX Pharmaceuticals, Inc.’s Form 8-K, filed March 24, 2026, for the meeting held March 23, 2026 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Chaim Hurvitz | 92% | — |
| Elect Director: Michael Taylor | 92% | — |
| 2. Approval of an amendment to the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the “ Omnibus Incentive Plan ” ) | 57% | Approved |
| 3. Ratification of Appointment of Auditors | 99% | Approved |
| 4. Approval of the compensation of the Company ’ s Named Executive Officers via a Non-Binding, Advisory Vote | 96% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.